Related Experiment Video
Updated: Jun 2, 2026
Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
IGFBP7, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans
1Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Background:
Loss of insulin-like growth factor-binding protein 7 (IGFBP7) has been found to be a critical step in the development of melanoma and colon cancer. To our knowledge, immunostaining of IGFBP7 in various dermatofibrosarcoma protuberans (DFSP) and dermatofibroma (DF) has not been studied before.
Objectives:
To assess the immunostaining of IGFBP7 in DFSPs and DFs and to ascertain whether IGFBP7 is superior to antibodies traditionally used in differentiating DFs from DFSPs.
Methods:
Immunohistochemical staining was performed on 28 cases of DFSP and 30 cases of DF, using antibodies to IGFBP7, CD34, factor XIIIa (FXIIIa), CD10 and stromelysin-3 (ST-3).
Results:
Six of 28 (21.4%) DFSP samples were positive for IGFBP7, whereas 28 of 30 (93.3%) DF samples were positive. CD34 was positive in 26 of 28 (92.9%) cases of DFSP and 4 of 30 (13.3%) cases of DF. FXIIIa staining was positive in 4 of 28 (14.3%) cases of DFSP and 28 of 30 (93.3%) cases of DF. CD10 staining was positive in 12 of 28 (42.9%) cases of DFSP and ST-3 staining was positive in 7 of 28 (25.0%) cases of DFSP. The preferential IGFP7 staining of DFSPs in comparison with DFs was statistically significant (P < 0.01).
Conclusions:
We confirmed that IGFBP7 is a negative immunohistochemical marker for DFSPs and the combination with CD34, FXIIIa and ST-3 immunostaining could make the distinction more reliable.
